Arjan BoltjesYesterday, me and my colleague took the #NightTrain to #Vienna, to join the #SIOPEN #translational research meeting.
Little under 10 hours from Utrecht.
I had to present our latest work on
#neuroblastoma. Beers to celebrate this event. 🍻
Important work, the #ITCC #SIOPEN #BEACON #neuroblastoma #trial
https://ascopubs.org/doi/10.1200/JCO.23.00458
In this trial Moreno et al. assessed possible added effects of #antiangiogenic agent #bevacizumab to #temozolomide treatment plus or minus #irinotecan or #topotecan for children with relapsed and refractory neuroblastoma.
Perhaps some early effects, but after 5-6 years rather depressing survival graphs, if I'm very honest.